Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.77 |
| ▸ | CTSL | P07711 | 2/20 | 0.76 |
| ▸ | CTSS | P25774 | 1/20 | 0.76 |
| ▸ | CTSK | P43235 | 1/20 | 0.76 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.70 |
| ▸ | TACR1 | P25103 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.62 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.62 |
| ▸ | ITGAL | P20701 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003555 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL850438 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL1486167 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL30976323 | 1.00 | ACE (0.77) | ACECTSLCTSSCTSKSCN9A | |
| Hydrochloric Acid SCHEMBL31472643 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL30699849 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| Fluoride SCHEMBL7445962 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| Fluoride SCHEMBL7445954 | 0.99 | ACE (0.75) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL11403615 | 0.96 | ACE (0.84) | ACECTSLCTSSCTSKSCN9A | |
| SCHEMBL27871524 | 0.96 | CTSL (0.76) | ACECTSLCTSSCTSKSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843638-A | Preparation and application of bifunctional molecular compound based on RSL3 induced GPX4 protein degradation | 沈阳药科大学 | 2024-04-09 | — | — | CN | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| CN-113773295-B | Synthesis method of monosubstituted dihydro chromone and application of monosubstituted dihydro chromone in treatment of pulmonary inflammation such as COPD (chronic disease) | 广东省科学院动物研究所 | 2023-06-20 | — | — | CN | claimed |
| CN-109432394-B | Octreotide acetate injection pharmaceutical composition and application thereof | 成都天台山制药有限公司 | 2022-02-01 | — | — | CN | claimed |
| EP-4698551-A1 | NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS | The University of Hong Kong (CN) | 2026-02-25 | — | — | EP | disclosed |
| CN-120647651-B | Beta-carboline-thiazole compound, preparation method thereof and application thereof as drug resistance reversal agent | 烟台大学 | 2025-11-07 | — | — | CN | disclosed |
| CN-120647651-A | Beta-carboline-thiazole compound, preparation method thereof and application thereof as drug resistance reversal agent | 烟台大学 | 2025-09-16 | — | — | CN | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2024217497-A1 | NOVEL SMALL MOLECULE AGONISTS OF INSULIN RECEPTOR (INSR) AS ANTI-DIABETES DRUGS | THE UNIVERSITY OF HONG KONG (CN) | 2024-10-24 | — | — | WO | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4034105-B1 | POLYMORPH FORM OF (R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | GALIMEDIX THERAPEUTICS INC (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-114805305-B | Compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114805305-A | Compound and application thereof | 成都诺和晟泰生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-4031557-A1 | METHODS FOR PRODUCING D-TRYPTOPHAN AND SUBSTITUTED D-TRYPTOPHANS | The Regents of the University of California (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2022-07-14 | — | — | US | disclosed |
| CN-114466652-A | Novel polymorphic crystal forms of (R) -2- [ 2-amino-3- (indol-3-yl) propionylamino ] -2-methylpropionic acid and uses thereof | 加利梅迪克斯治疗公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3966234-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2022-03-16 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-109432394-B | Octreotide acetate injection pharmaceutical composition and application thereof | 成都天台山制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220155-A1 | VASCULAR CHOLESTEROL INHIBITORS AND USE THEREOF | LDLR, APOB, HDLBP | ACE 1604/4885CTSL 2454/4885CTSS 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.